Cessatech operates in the pharmaceutical industry. The company specializes in research and development of analgesic nasal sprays that are also used for the treatment of acute pain conditions in children. In addition to the main business, associated ancillary services and related products are also offered. The business is operated globally with the largest presence in the Nordic market. Cessatech was founded in 2020 and is headquartered in Copenhagen.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Jes Trygved | 5,32 | 5,32 | 2024-12-31 |
| Bettina Nygaard Nielsen | 3,72 | 3,72 | 2022-12-29 |
| Steen Winther Henneberg | 3,72 | 3,72 | 2022-12-29 |
| Henriksen Group Aps | 2,87 | 2,87 | 2022-12-29 |
| Martin Olin | 2,05 | 2,05 | 2024-12-31 |
| Adam Steensberg | 1,20 | 1,20 | 2023-12-31 |
| Rachel Curtis Gravesen | 1,17 | 1,17 | 2024-12-31 |
| Charlotte Videbaek | 1,00 | 1,00 | 2024-12-31 |
| Anders Dyhr Dombernowsky-Tof | 0,29 | 0,29 | 2024-12-31 |
| Peter Birk | 0,07 | 0,07 | 2023-12-31 |
2025-11-13 Delårsrapport 2025-Q3
2026-02-27 Bokslutskommuniké 2025
